Journal
ACS NANO
Volume 7, Issue 12, Pages 10452-10464Publisher
AMER CHEMICAL SOC
DOI: 10.1021/nn405004f
Keywords
cancer; cisplatin; drug resistance; nanoscale drug delivery platforms; membrane trafficking; nanotechnology; chemotherapy; abnormal membrane proteins
Categories
Funding
- National Natural Science Foundation for Distinguished Young Scholars of China [31225009]
- National Science and Technology support program [2012BAF13B05]
- National Natural Science Foundation of China [81171455]
- National Key Basic Research Program of China [2009CB930200]
- Chinese Academy of Sciences (CAS) Hundred Talents Program
- Intramural Research Program of the National Institutes of Health, National Cancer Institute
Ask authors/readers for more resources
The development of cellular resistance to platinum-based chemotherapies is often associated with reduced intracellular platinum concentrations. In some models, this reduction is due to abnormal membrane protein trafficking, resulting in reduced uptake by transporters at the cell surface. Given the central role of platinum drugs in the clinic, it is critical to overcome cisplatin resistance by bypassing the plasma membrane barrier to significantly increase the intracellular cisplatin concentration enough to inhibit the proliferation of cisplatin-resistant cells. Therefore, rational design of appropriate nanoscale drug delivery platforms (nDDPs) loaded with cisplatin or other platinum analogues as payloads is a possible strategy to solve this problem. This review will focus on the known mechanism of membrane trafficking in cisplatin-resistant cells and the development and employment of nDDPs to improve cell uptake of cisplatin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available